Valeant Pharmaceuticals used $811 million of the $819.9 million it received for selling Dendreon Pharmaceuticals to pay down some of the company's senior secured loans.
Here's what you should know:
1. Valeant has paid all mandatory amortizations through 2019.
2. Since the first quarter of fiscal year 2016, Valeant reduced its debt by more than $4.3 billion.
3. Valeant executives believe the company will pay approximately $5 billion in debt by February 2018.
4. Valeant sold Dendreon Pharmaceuticals to Sanpower Group on June 29. .